IO#11 Additional Water Installed & IO#12 Progress

Iofina touts major future iodine output, but offers no hard numbers or financials.

What the company is saying

Iofina positions the installation of a second brine source at IO#11 as a key operational milestone, claiming it will drive a 45-65 metric tonne annual increase in crystalline iodine production, or a 50% uplift for the plant. The company frames this as evidence of both expanded capacity and greater operational resilience, but does not provide actual production figures. Progress on IO#12 is highlighted as on schedule, with promises that it will be the group’s largest plant and deliver 170-220 MT of iodine annually once operational by end Q3 2026. The announcement repeatedly references Iofina’s status as the second-largest iodine producer in North America and its specialty chemical credentials, aiming to reinforce credibility and scale. The language is optimistic and forward-looking, emphasizing anticipated growth and pathway to 2,000 MT annual production, but avoids specifics on current output or financial performance. No mention is made of costs, capex, or profitability, and there is no discussion of risks or market demand.

What the data suggests

The only realised fact is the completion of the additional brine water source at IO#11 and the plant now using two brine sources. All production increases (45-65 MT, 50% uplift) are projections without baseline data, so the magnitude of improvement cannot be independently verified. IO#12’s expected 170-220 MT output is also a forward-looking estimate, with no comparative numbers for existing plants or evidence of construction progress. Claims of being the second-largest producer in North America are unsupported by any market share or volume data. No financial metrics—such as revenue, profit, cash flow, or even plant-level production—are disclosed, making it impossible to assess the company’s financial trajectory. The data quality is insufficient for rigorous analysis, as most claims are aspirational and lack substantiation.

Analysis

The announcement uses positive language to highlight operational milestones and future growth, but the majority of key claims are forward-looking projections rather than realised facts. While the installation of the additional brine source at IO#11 is a completed milestone, the expected production increases (45-65 MT, 50% uplift) are not yet realised and lack supporting baseline data. The largest future benefit, IO#12's anticipated production, is long-dated (operational by end Q3 2026) and presented without any financial or profitability metrics. There is a clear gap between the narrative of substantial growth and the absence of disclosed revenue, profit, or even actual production figures. The capital intensity flag is triggered by the ongoing construction of IO#12, which requires significant investment with benefits only expected in the long term. Overall, the tone is moderately inflated relative to the evidence, with most claims remaining aspirational.

Risk flags

• ●The company provides no actual production, revenue, or profitability figures, making it impossible to verify claims of growth or operational improvement. This lack of disclosure increases the risk that projected benefits will not materialise as described.
• ●All major claims about increased output at IO#11 and IO#12 are forward-looking and unsupported by baseline or comparative data. Without evidence of current performance, there is a material risk that the uplift is overstated or delayed.
• ●IO#12’s construction is capital intensive and the timeline stretches to at least Q3 2026. Delays, cost overruns, or operational setbacks could materially impact the projected benefits and financial returns.
• ●The claim of being the second-largest iodine producer in North America is unsubstantiated by any market share or competitor data, raising questions about the accuracy of the company’s market positioning.

Bottom line

This announcement signals Iofina’s ambition to expand iodine output, but nearly all key claims are projections without supporting numbers. Investors are given no current production, revenue, or profitability data, and the promised benefits from IO#11 and IO#12 remain unproven and long-dated. The absence of cost, capex, or margin disclosures means financial impact cannot be assessed. The narrative is optimistic but not substantiated by hard evidence, and the company’s market position is asserted without proof. For this to become actionable, Iofina would need to release actual production increases, baseline figures, and profitability metrics. Until then, the most important takeaway is that the growth story is aspirational, not yet demonstrated.

Announcement summary

(AIM: IOF) Iofina plc announced that the additional brine water source at IO#11 has now been fully installed, which is expected to increase crystalline iodine production at IO#11 by approximately 45-65 metric tonnes annually, representing an expected 50% increase in annual production from the plant. IO#11 now utilises two separate brine water sources, providing additional production capacity and greater operational resilience. Construction of IO#12 continues to progress as planned, with the plant on track to become operational by the end of Q3 2026. Once fully operational, IO#12 is expected to be the Group's largest IOsorb® plant, with annual crystalline iodine production anticipated to be between 170-220 MT. Iofina is the second-largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical. Iofina currently operates eight producing IOsorb® plants in Oklahoma. Iofina Chemical celebrated its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

Disagree with this article?